BIIB Stock DD Biogen Idec, Inc. 08/05/2014 16:13:06

New Post Public Reply Private Reply Replies (0) Message Board

Aug 5, 2014 at 5:13 PM

BIIB Biogen Idec, Inc. $BIIB Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=BIIB&...mp;yt0=Go!

Last Updated: 08/05/2014 16:13:02

Current Price and Quotes
Last Price
Previous Close 326.55 Open 325.58
Daily Range 322.14 - 328.55 52wk Range 203.55 - 358.89
Volume 1,144,589 Dividend N/A
Average Vol (3m) 1,162,651 Yield N/A

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 6,932,199 5,516,461 5,048,634 4,716,423
Cost of Revenue 857,726 545,494 466,780 400,262
Gross Profit 6,074,473 4,970,967 4,581,854 4,316,161
Operating Expenses

Research and Development 1,444,053 1,334,919 1,219,602 1,248,604
Sales, General and Admin. 1,796,861 1,622,562 1,409,969 1,289,611
Non-Recurring Items - 2,225 19,026 320,129
Other 342,948 202,204 208,566 208,928
Operating Income 2,515,509 1,855,849 1,724,691 1,248,889
Income From Continuing Operations

Add'l Income/Expense Items (10,032) 46,048 (13,477) (18,983)
Earnings Before Interest and Tax 2,505,477 1,901,897 1,711,214 1,229,906
Interest Expense - - - -
Earnings Before Tax 2,505,477 1,901,897 1,711,214 1,229,906
Income Tax 601,014 470,554 444,528 331,333
Minority Interest - - 32,258 (106,700)
Equity Earnings Unconsolidated Subsidiary (17,224) (4,518) - -
Net Income Cont. Operations 1,887,239 1,426,825 1,234,428 1,005,273
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 1,862,341 1,380,033 1,234,428 1,005,273
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 1,862,341 1,380,033 1,234,428 1,005,273

Recent News

Aug 5, 2014 Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
Aug 4, 2014 BioMed Realty Trust To Webcast Investor Day 2014
Aug 1, 2014 Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
Jul 30, 2014 Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Jul 29, 2014 Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
Jul 24, 2014 The Zacks Analyst Blog Highlights: Biogen Idec, Roche Holding, AbbVie, AmSurg and Acadia Healthcare
Jul 23, 2014 PLEGRIDY(TM) (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
Jul 23, 2014 Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year
Jul 22, 2014 Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
Jul 17, 2014 Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept

1
2
3
4
5
6
next >

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ardelyx Securities Fraud Suit: Key Investor Moves

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

Raken Debuts Change Orders: A Game-Changer for Builds

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

PrideStaff: 8 Years Strong on Franchise Times Top 400

Where PrideStaff Stands in the Franchise Landscape Here's something the staffing world can't ignore: PrideStaff nailed it again, landing among the giants on the Franchise Times Top 400 for the eighth straight year. Sitting at number 217, this ain't just a lucky streak—this is a sustained homerun, my friends. Consistency Is Key, And They're Holding It Consider this...

Ajman Tourism Department Hits Internal Audit Milestone

A Nod to Standards in Ajman's Tourism Department Folks, it's not every day you see a government department get this kind of spotlight in the internal audit arena, yet here we are. The Ajman Department of Tourism, Culture and Media has snagged Full Conformance with Internal Audit Quality Standards. That’s not just some random feather in their cap but a signal flare in...

Teamsters Secure Landmark Deal for SF Parking Workers

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Lupin Secures FDA Nod for Key Injectable Drug

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...

CME Group Unveils First Baseball Futures Market

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Mexico's Beaches Shine in 2026 Best America Rankings

Mexican Shores Turning Heads in 2026 This isn’t just another wave in tourism news; it’s a tidal shift towards Mexico’s sizzling beaches claiming some prime spots on the global travel stage. If you’ve got an eye for tourism dynamics, listen up because Mexico’s sun-soaked shores just snagged six spots among the top 20 beaches in the Americas, according to the...